nebivolol
Generic: NEBIVOLOL HYDROCHLORIDE·Brand: BYSTOLIC, Bystolic, Byvalson, NEBIVOLOL HYDROCHLORIDE
nebivolol: sourced relationships with 2 companies · 2 FDA decisions.
nebivolol evidence translation
What we can confirm
2 FDA records
What it means
More than one company relationship is source-backed. Until you choose one, AI stays drug-only and does not guess ownership.
What to watch
Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected
Prepared research question
What is verified about nebivolol, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
Dated Pipeline Records (2)
| Company | Dated record stage |
|---|---|
| Allergan plc (AGN) Reported 2007-12-17 · Current development: unknownSource | Approved |
| ANI PHARMACEUTICALS INC (ANIP) Reported 2015-04-16 · Current development: unknownSource | Approved |
FDA Decisions2 records
Approval1. INDICATIONS AND USAGE BYSTOLIC is a beta-adrenergic blocking agent indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) 1.1 Hypertension BYSTOLIC is indicated for the treatment of hypertension, to lower blood pressure [see Clinical Studies ( 14.1 )]. BYSTOLIC may be used alone or in combination with other antihypertensive agents [see Drug(AGN)FDA ↗
NDA021742Type 1 - New Molecular EntityStandardOralTablet
Frequently asked questions
Which companies have sourced relationships with nebivolol?
nebivolol has dated SEC/FDA relationship records for Allergan plc, ANI PHARMACEUTICALS INC.
What is nebivolol's latest FDA decision?
The most recent tracked FDA decision for nebivolol is Approval, dated April 16, 2015.